Abstract
The products resulting from the techniques and processes of biotechnology continue to grow at an exponential rate, and the expectations are that an even greater percentage of drug development and clinically utilized pharmaceuticals worldwide will be classified as biologics. A recent Pharmaceutical Research and Manufacturers of America report notes that there are currently over 8000 medicines in clinical development globally and 74% in the pipeline have the potential to be first-in-class treatments. Most pertinent to this textbook, the majority of these medicines in development were impacted directly or indirectly by biotechnologies at one or more points during their discovery or development lifetime via target identification, and/or lead identification, and/or lead optimization, and/or clinical development and evaluation and/or product production. Pharmaceutical biotechnology techniques are at the core of most methodologies used today for drug discovery and development of both biologics and small molecules. While recombinant DNA technology and hybridoma techniques were the major methods utilized in pharmaceutical biotechnology through most of its earlier historical timeline, our ever-widening understanding of human cellular function and disease processes and a wealth of additional and innovative biotechnologies such as gene editing and cell therapy have been, and will continue to be, developed in order to harvest the information found in the human genome and developed into first-in-class therapies. These technological advances will provide a better understanding of the relationship between genetics and biological function, unravel the underlying causes of disease, explore the association of genomic variation and drug response, enable personalized and precision medicine, enhance pharmaceutical research, and fuel the discovery and development of new and novel biopharmaceuticals. These revolutionary technologies and additional biotechnology-related techniques are improving the very competitive and costly process of drug development of new medicinal agents, diagnostics, and medical devices. Some of the technologies and techniques described in this chapter are both well established and commonly used applications of biotechnology producing clinically utilized medicines as well as potential therapeutic products now in the developmental pipeline. New techniques are emerging at a rapid and unprecedented pace and their full impact on the future of molecular medicine will turn dreams into realities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adli M (2018) The CRISPR tool kit for genome editing and beyond. Nat Commun 9:1–13. https://doi.org/10.1038/s41467-018-04252-2
Akhoon N (2021) Precision medicine: a new paradigm in therapeutics. Int J Prev Med 12(12):1–7. https://doi.org/10.4103/ijpvm.IJPVM_375_19
Alexander-Dann B, Pruteanu LL, Oerton E, Sharma N, Berindan-Neagoe I, Módos D, Bender A (2018) Developments in toxicogenomics: understanding and predicting compound-induced toxicity from gene expression data. Mol Omics 14(4):218–236. https://doi.org/10.1039/c8mo00042e
Aronson JK, Ferner RE (2017) Biomarkers-a general review. Curr Protoc Pharmacol 76:9.23.1–9.23.17. https://doi.org/10.1002/cpph.19
Avela HF, Sirén H (2020) Advances in lipidomics. Clin Chim Acta 510:123–141. https://doi.org/10.1016/j.cca.2020.06.049
Bachtiar M, Ooi BNS, Wang J, Jin Y, Tan TW, Chong SS, Lee CGL (2019) Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms. Pharmacogenomics J 19:516–527. https://doi.org/10.1038/s41397-019-0096-y
BBC News (2022) Man gets genetically-modified pig heart in world-first transplant. https://www.bbc.com/news/world-us-canada-59944889. Accessed 1 Aug 2022
Bertolini LR, Meade H, Lazzarotto CR, Martins LT, Tavares KC, Bertolini M, Murray JD (2016) The transgenic animal platform for biopharmaceutical production. Transgenic Res 25:329–343. https://doi.org/10.1007/s11248-016-9933-9
Biesecker LG, Spinner NB (2013) A genomic view of mosaicism and human disease. Nat Rev Genet 14:307–320. https://doi.org/10.1038/nrg3424
Bingol K, Bruschweller-Li L, Li D, Zhang B, Xie M, Bruschweiler R (2016) Emerging new strategies for successful metabolite identification in metabolomics. Bioanalysis 8:557–573. https://doi.org/10.4155/bio-2015-0004
Biospace (2022) The market for precision medicine. https://www.biospace.com/article/precision-medicine-market-size-to-hit-us-140-69-bn-by-2028/. Accessed 10 Sept 2022
Briganti G, Le Moine O (2020) Artificial intelligence in medicine: today and tomorrow. Front Med 7:1–6. https://doi.org/10.3389/fmed.2020.00027
Cai W, Liu Z, Miao L, Xiang X (2020) Pharmacogenomics in precision medicine: from a perspective of ethnic differences. Springer, Berlin
Cao WQ, Liu MQ, Kong SY, Wu MX, Huang ZZ, Yang PY (2020) Novel methods in glycomics: a 2019 update. Expert Rev Proteomics 17(1):11–25. https://doi.org/10.1080/14789450.2020.1708199
Chakravarty D, Solit DB (2021) Clinical cancer genomic profiling. Nat Rev Genet 22:483–501. https://doi.org/10.1038/s41576-021-00338-8
Chaudhry SR, Muhammad S, Eidens M, Klemm M, Khan D, Efferth T, Weisshaar MP (2014) Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms. Curr Drug Metab 15:711–718. https://doi.org/10.2217/pgs-2017-0194
Chen Y, Zhou J, Wang L (2021) Role and mechanism of gut microbiota in human disease. Front Cell Infect Microbiol 11(3):625913. https://doi.org/10.3389/fcimb.2021.625913
Chen W, Anothaisintawee T, Butani D, Wang Y, Zemlyanska Y, Boon C, Wong N, Virabhak S, Hrishikesh MA, Teerawattananon Y (2022) Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis. BMJ Open 12:e057537. https://doi.org/10.1136/bmjopen-2021-057537
Chouchana L, Narjoz C, Roche D, Golmard JL, Pineau B, Chatellier G, Beaune P, Loriot MA (2014) Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics 15:745–757. https://doi.org/10.2217/pgs.14.32
Clark SJ, Lee HJ, Smallwood SA, Kelsey G, Reik W (2016) Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. Genome Biol 17:72–82. https://doi.org/10.1186/s13059-016-0944-x
Cortess D, Leung J, Ryl A, Lieu J (2019) Pharmacy informatics: where medication use and technology meet. Can J Hosp Pharm 72(4):320–326
Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J (2014) Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol 34:281–299. https://doi.org/10.3109/07388551.2013.793649
Dai X, Blancafort P, Wang P, Sgro A, Thompson EW, Ostrikov KK (2020) Innovative precision gene-editing tools in personalized cancer medicine. Adv Sci 7(12):1902552. https://doi.org/10.1002/advs.201902552
Doudna JA (2020) The promise and challenge of therapeutic genome editing. Nature 578(229):236. https://doi.org/10.1038/s41586-020-1978-5
Doytchinova I (2022) Drug design-past, present, future. Molecules 27(5):1496. https://doi.org/10.3390/molecules27051496
Dugger SA, Platt A, Goldstein DB (2018) Drug development in the era of precision medicine. Nat Rev Drug Discov 17:183–196. https://doi.org/10.1038/nrd.2017.226
Dupree EJ, Jayathirtha M, Yorkey H, Mihasan M, Petre BA, Darie CC (2020) A critical review of bottom-up proteomics: the good, the bad, and the future of this field. Proteomes 8(3):14–40. https://doi.org/10.3390/proteomes8030014
Eder J, Herrling PL (2016) Trends in modern drug discovery. Handb Exp Pharmacol 232:3–20. https://doi.org/10.1007/164_2
EMBL-EBI (2022) European molecular biology organization–European bioinformatics institute. https://wwwemblorg/services-facilities/. Accessed 10 Sept 2022
Emery JD (2017) Pharmacogenomic testing and warfarin: what evidence has the GIFT trial provided? JAMA 318(12):1110–1112. https://doi.org/10.1001/jama.2017.11465
Emmerich CH, Gamboa LM, Hofmann MCJ, Bonin-Andresen M, Arbach O, Schendel P, Gerlach B, Hempel K, Bespalov A, Dirnagl U, Parnham MJ (2021) Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov 20:64–81. https://doi.org/10.1038/s41573-020-0087-3
Ersek JL, Black LJ, Thompson MA, Kim ES (2018) Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices. Am Soc Clin Oncol Educ Book 38:188–196. https://doi.org/10.1200/EDBK_200633
FDA (2022) Drugs in scientific research. https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm. Accessed 10 Sept 2022
Feinberg AP (2018) The key role of epigenetics in human disease prevention and mitigation. N Engl J Med 378:1323–1334. https://doi.org/10.1056/NEJMra1402513
Feinberg AP, Irizarry RA, Fradin D, Aryee MJ, Murakami P, Aspelund T, Eirksdottir G, Harris TB, Launer L, Gudnason V, Fallin MD (2010) Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci Transl Med 2:45–51. https://doi.org/10.1126/scitranslmed.3001262
Finn C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J (2017) The druggable genome and support for target identification and validation in drug development. Sci Transl Med 9(383):1–15. https://doi.org/10.1126/scitranslmed.aag1166
Gentile F, Agrawal V, Hsing M, Ton A-T, Ban F, Norinder U, Gleave ME, Cherkasov A (2020) Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent Sci 6(6):939–949. https://doi.org/10.1021/acscentsci.0c00229
Gerszberg A, Hnatuszko-Konka K (2022) Compendium on food crop plants as a platform for pharmaceutical protein production. Int J Mol Sci 23:1–21. https://doi.org/10.3390/ijms23063236
Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M (2017) Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov 16(1):1. https://doi.org/10.1038/nrd.2016.234
Giunta S (2021) Decoding human cancer with whole genome sequencing: a review of PCAWG project studies published in February 2020. Cancer Metastasis Rev 40:909–924. https://doi.org/10.1007/s10555-021-09969-z
Glass JI, Smith HO, Hutchison III CA, Alperovich NY, Assad-Garcia N (2007) Minimal bacterial genome. United States patent application 20070122826, May 31, 2007
Globe News Wire (2022) The protein engineering product and services market estimates. https://wwwglobenewswirecom/news-release/2022/06/17/2464481/0/en/Protein-Engineering-Market-Size-Worth-USD-3-02-Billion-by-2027-at-7-62-CAGR-Report-by-Market-Research-Future-MRFRhtml. Accessed 10 Sept 2022
Ha VTD, Frizzo-Barker J, Chow-White P (2018) Adopting clinical genomics: a systematic review of genomic literacy among physicians in cancer care. BMC Med Genet 11:18–36. https://doi.org/10.1186/s12920-018-0337-y
Hanczyc MM (2020) Engineering life: a review of synthetic biology. Artif Life 26(2):260–273. https://doi.org/10.1162/artl_a_00318
HCA (2022) The international human cell atlas. https://www.humancellatlas.org/. Accessed 10 Sept 2022
Höglund M (1998) Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)–what is the difference? Med Oncol 15:229–233. https://doi.org/10.1007/BF02787205
Höhne M, Kabisch J (2016) Brewing painkillers: a yeast cell factory for the production of opioids from sugar. Angew Chem Int Ed Engl 55:1248–1125. https://doi.org/10.1002/anie.201510333
HPP (2022) The human proteome project. https://hupo.org/human-proteome-project. Accessed 10 Sept 2022
HuBMAP (2022) Human biomolecular atlas program. https://commonfund.nih.gov/hubmap. Accessed 10 Sept 2022
IMPC (2022) The international mouse phenotyping consortium. http://www.mousephenotype.org/. Accessed 10 Sept 2022
IOM (Institute of Medicine) (2017) Accelerating progress toward continuously learning. The National Academies Press, Washington, DC
Jiang J, Tian F, Cai Y, Qian X, Coatello CE, Ying W (2014) Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin. Anal Bioanal Chem 406:6265–6274. https://doi.org/10.1007/s00216-014-8037-8
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821. https://doi.org/10.1126/science.1225
Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14:49–55. https://doi.org/10.1038/nrm3486
Karoui ME, Hoyos-Flight M, Fletcher L (2019) Future trends in synthetic biology—a report. Front Bioeng Biotechnol 7(7):175. https://doi.org/10.3389/fbioe.2019.00175
Keathley J, Garneau V, Zavala-Mora D, Heister RR, Gauthier E, Morin-Bernier J, Green R, Vohl M-C (2021) A systematic review and recommendations around frameworks for evaluating scientific validity in nutritional genomics. Front Nutr 8:789215. https://www.frontiersin.org/article/10.3389/fnut.2021.7892158
Kelsey G, Stegle O, Reik W (2017) Single-cell epigenomics: recording the past and predicting the future. Science 358:69–75. https://doi.org/10.1126/science.aan68
Klompe SE, Vo PLH, Halpin-Healy TS, Sternberg SH (2019) Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature 571(7764):219–225. https://doi.org/10.1038/s41586-019-1323-z
Korendovych IV (2018) Rational and Semirational protein design. Methods Mol Biol 1685:15–23. https://doi.org/10.1007/978-1-4939-7366-8_2
Korendovych IV, DeGrado WF (2020) De novo protein design, a retrospective. Q Rev Biophys 53:e3. https://doi.org/10.1017/S0033583519000131
Krassowski M, Vivek D, Sangram SK, Misra BB (2020) State of the field in multi-omics research: from computational needs to data mining and sharing. Front Genet 11:1–27. https://doi.org/10.3389/fgene.2020.610798
Kulkarni A, Anderson AG, Merullo DP, Konopka G (2019) Beyond bulk: a review of single cell transcriptomics methodologies and applications. Curr Opin Biotechnol 58:129–136. https://doi.org/10.1016/j.copbio.2019.03.001
Kwapisz D (2017) The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med 5:46. https://doi.org/10.21037/atm.2017.01.32
Kwong GA, Ghosh S, Gamboa L, Patriotis C, Srivastava S, Bhatia SN (2021) Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat Rev Cancer 21:655–668. https://doi.org/10.1038/s41568-021-00389-3
Lam JT, Gutierrez MA, Shah S (2021) Pharmacogenomics: a primer for clinicians. McGraw Hill, New York
Lamas-Toranzo I, Guerrero-Sánchez J, Miralles-Bover H, Alegre-Cid G, Pericuesta E, Bermejo-Álvarez P (2017) CRISPR is knocking on barn door. Reprod Domest Anim 52(Suppl 4):39–47. https://doi.org/10.1111/rda.13047
Li W, Li M, Pu X, Guo Y (2017) Distinguishing the disease-associated SNPs based on composition frequency analysis. Interdiscip Sci 9:459–467. https://doi.org/10.1007/s12539-017-0248-1
Lindon JC, Nicholson JK (2014) The emergent role of metabolic phenotyping in dynamic patient stratification. Expert Opin Drug Metab Toxicol 10:915–919. https://doi.org/10.1517/17425255.2014.922954
Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA (2021) Organs-on-chips: into the next decade. Nat Rev Drug Discov 20:345–361. https://doi.org/10.1038/s41573-020-0079-3
Lutz S, Iamurri SM (2018) Protein engineering: past, present, and future. Methods Mol Biol 1685:1–12. https://doi.org/10.1007/978-1-4939-7366-8_1
Madhavan S, Subramaniam S, Brown TD, Chen JL (2018) Art and challenges of precision medicine: interpreting and integrating genomic data into clinical practice. Am Soc Clin Oncol Educ Book 38:546–553
Mapanao AK, Voliani V (2020) Three-dimensional tumor models: promoting breakthroughs in nanotheranostics translational research. Appl Mater Today 19:100552. https://doi.org/10.1016/j.apmt.2019.100552
McGuire AL, Gabriel S, Tishkoff SA, Wonkam A, Chakravarti A, Furlong EEM, Treutlein B, Meissner A, Chang HY, Lopez-Bigas N, Segal E, Kim JS (2020) The road ahead in genetics and genomics. Nat Rev Genet 21:581–596. https://doi.org/10.1038/s41576-020-0272-6
McInnes G, Yee SW, Pershad Y, Altman RB (2021) Genomewide association studies in pharmacogenomics. Clin Pharmacol Ther 110:637–648. https://doi.org/10.1002/cpt.2349
Miao Z, Humphreys BD, McMahon AP, Kim J (2021) Multi-omics integration in the age of million single-cell data. Nat Rev Nephrol 17:710–724. https://doi.org/10.1038/s41581-021-00463-x
Minikel EV, Karczewski KJ, Martin HC, Cummings BB, Whiffin N, Rhodes D, Alfoldi J, Trembath RC, van Heel DA, Daly MJ, Genome Aggregation Database Production Team, Genome Aggregation Database Consortium, Schreiber SL, DG MA (2020) Evaluating drug targets through human loss-of-function genetic variation. Nature 581:459–464. https://doi.org/10.1038/s41586-020-2267-z
Mohanta TK, Mishra AK, Al-Harrasi A (2021) The 3D genome: from structure to function. Int J Mol Sci 22(21):11585–11591. https://doi.org/10.3390/ijms222111585
Molina-Espeja P, Vina-Gonzalez J, Gomez-Fernandez BJ, Martin-Diaz J, Garcia-Ruiz E, Miguel A (2016) Beyond the outer limits of nature by directed evolution. Biotechnol Adv 34:754–767. https://doi.org/10.1016/j.biotechadv.2016.03.008
Narimatsu Y, Bull C, Chen YH, Wandall HH, Yang Z, Clausen H (2021) Genetic glycoengineering in mammalian cells. J Biol Chem 296:100448. https://doi.org/10.1016/j.jbc.2021.100448
National Human Genome Institute (2022) Knockout-mice-fact-sheet. https://wwwgenomegov/about-genomics/fact-sheets/Knockout-Mice-Fact-Sheet. Accessed 1 Aug 2022
National Human Genome Research Institute (2023) https://www.genome.gov/about-genomics/fact-sheets/Knockout-Mice-Fact-Sheet. Accessed 13 September 2023
Nature (2018) Method of the year 2017: organoids. Nat Methods 15:1. https://doi.org/10.1038/nmeth.4575
Nature (2020) Method of the year 2019: single-cell multimodal omics. Nat Methods 17:1. https://doi.org/10.1038/s41592-019-0703-5
NCATS (2022) National Center for Advanced Translational Medicine. https://ncats.nih.gov/heal/funding/call-for-proposals/opportunities/heal-target-and-compound-library. Accessed 10 Sept 2022
NCBI (2022) National Center for Biotechnology Information, NCBI, of the National Institutes of Health. http://www.ncbi.nlm.nih.gov. Accessed 10 Sept 2022
Nidhi S, Anand U, Oleksak P, Tripathi P, Lal JA, Thomas G, Kuca K, Tripathi V (2021) Novel CRISPR-Cas systems: an updated review of the current achievements, applications, and future research perspectives. Int J Mol Sci 22(7):1–42. https://doi.org/10.3390/ijms22073327
NIH Human Microbiome Portfolio Analysis Team (2019) A review of 10 years of human microbiome research activities at the US National Institutes of Health, fiscal years 2007-2016. Microbiome 7:31. https://doi.org/10.1186/s40168-019-0620-y
Omenn GS, Lane L, Overall CM, Paik YK, Cristea IM, Corrales FJ, Lindskog C, Weintraub S, Roehrl MHA, Liu S, Bandeira N, Srivastava S, Chen YJ, Aebersold R, Moritz RL, Deutsch EW (2021) Progress identifying and analyzing the human proteome: 2021 metrics from the HUPO human proteome project. J Proteome Res 20(12):5227–5240. https://doi.org/10.1021/acs.jproteome.1c00590
Papastergiou J, Tolios P, Li W, Li J (2017) The innovative Canadian Pharmacogenomic screening initiative in community pharmacy (ICANPIC) study. J Am Pharm Assoc 57:624–629. https://doi.org/10.1016/j.japh.2017.05.006
Paul A, Paul S (2014) The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci (Landmark Ed) 19:605–618. https://doi.org/10.2741/4230
PhRMA (2021) 2021 industry profile: medicines are transforming the trajectory of many diseases. https://phrma.org/resource-center/Topics/Medicines-in-Development/2021-Industry-Profile-Toolkit-Medicines-are-Transforming-the-Trajectory-of-Many-Diseases Accessed 7 Apr 2022
Premsrirut P (2017) Drug discovery in the age of big data. Drug Discov World 17:8–15
Primorac D, Bach-Rojecky L, Vađunec D, Juginović A, Žunić K, Matišić V, Skelin A, Arsov B, Erceg D, Ivkošić IE, Molnar V, Ćatić J, Mikula I, Boban L, Primorac L, Esquivel B, Donaldson M (2020) Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of big data. Pharmacogenomics 21(2):141–156. https://doi.org/10.2217/pgs-2019-0134
Prokopuk L, Western PS, Stringer JM (2015) Transgenerational epigenetic inheritance: adaptation through the germline epigenome? Epigenomics 7(5):829–846. https://doi.org/10.2217/epi.15.36
Przybyla L, Gilbert LA (2022) A new era in functional genomics screens. Nat Rev Genet 23:9–103. https://doi.org/10.1038/s41576-021-00409-w
Pushpakom S, Iorio F, Eyers P, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41–58. https://doi.org/10.1038/nrd.2018.168
Qin C, Tanis KQ, Podtelezhnikov AA, Glaab WE, Sistare FD, DeGeorge JJ (2016) Toxicogenomics in drug development: a match made in heaven? Expert Opin Drug Metab Toxicol 12(8):847–849. https://doi.org/10.1080/17425255.2016.1175437
Reddy AVB, Yusop Z, Jaafar J, Madhavi V, Madhavi G (2016) Advances in drug discovery: impact of genomics and role of analytical instrumentation. Curr Drug Discov Technol 13:211–224. https://doi.org/10.2174/1570163813666160930122643
Relling MV, Evans WE (2015) Pharmacogenomics in the clinic. Nature 526:343–350. https://doi.org/10.1038/nature15817
Sagner M, McNeil A, Puska P, Auffray C, Price ND, Hood L, Lavie CJ, Han Z, Chen Z, Brahmachari SK, McEwen BS, Soares MB, Balling R, Epel E, Arena R (2017) The P4 health spectrum–a predictive, preventive, personalized and participatory continuum for promoting healthspan. Prog Cardiovasc Dis 59:506–521. https://doi.org/10.1016/j.pcad.2016.08.002
SBGN (2022) Examples of complex systems biology-derived protein interaction networks. http://sbgn.github.io/sbgn/examples. Accessed 10 Sept 2022
Scheinfeldt LB (2022) Pharmacogenomics: from basic research to clinical implementation. J Pers Med 11:800
Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, Fisher J, Jansen JM, Duca JS, Rush TS, Zentgraf M, Hill JE, Krutoholow E, Kohler M, Blaney J, Funatsu K, Luebkemann C, Schneider G (2020) Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov 19:353–364. https://doi.org/10.1038/s41573-019-0050-3
Schumacher S, Muekusch S, Seitz H (2015) Up-to-date applications of microarrays and their way to commercialization. Microarrays (Basel) 4:196–213. https://doi.org/10.3390/microarrays4020196
Schwarze K, Buchanan J, Taylor J, Wordsworth S (2018) Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Gen Med 20(10):1122–1130. https://doi.org/10.1038/gim.2017.247
Sebastian B, Boch J (2021) TALE and TALEN genome editing technologies. Gene Genome Ed 2:1–14. https://doi.org/10.1016/j.ggedit.2021.100007
Service RF (2018) Protein evolution earns chemistry Nobel. Science 362(6411):142. https://doi.org/10.1126/science.362.6411.142
Singh RK, Lee JK, Selvaraj C, Singh R, Li J, Kim SY, Kalia VC (2018) Protein engineering approaches in the post-genomic era. Curr Protein Pept Sci 19(1):5–15. https://doi.org/10.2174/1389203718666161117114243
Smaglik P (2017) The genetic microscope. Nature 545:S25–S27. https://doi.org/10.1038/545S25a
Smirnov A, Fishman V, Yunusova A, Korablev A, Serova I, Skryabin BV, Rozhdestvensky TS, Battulin N (2020) DNA barcoding reveals that injected transgenes are predominantly processed by homologous recombination in mouse zygote. Nucleic Acids Res 48(2):719–735. https://doi.org/10.1093/nar/gkz1085
Sofi MY, Shafi A, Masoodi KZ (2022) Nucleic acid sequence databases. In: Sofi MY, Shafi A, Masoodi KZ (eds) Bioinformatics for everyone. Academic, Cambridge, pp 25–36. https://www.sciencedirect.com/science/article/pii/B9780323911283000161
Sonehara K, Okada Y (2021) Genomics-driven drug discovery based on disease-susceptibility genes. Inflamm Regener 41:8. https://doi.org/10.1186/s41232-021-00158-7
Tang X, Huang Y, Lei J, Luo H (2019) The single-cell sequencing: new developments and medical applications. Cell Biosci 9:53. https://doi.org/10.1186/s13578-019-0314-y
Tang TC, An B, Huang Y, Vasikaran S, Wang Y, Jiang X, Lu TK, Zhong C (2021) Materials design by synthetic biology. Nat Rev Mater 6:332–350. https://doi.org/10.1038/s41578-020-00265-w
Tavassoly I, Goldfarb J, Iyengar R (2018) Systems biology primer: the basic methods and approaches. Essays Biochem 62(4):487–500. https://doi.org/10.1042/EBC20180003
The International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921. https://doi.org/10.1038/35057062
Tost J (2020) 10 years of epigenomics: a journey with the epigenetic community through exciting times. Epigenomics 12(2):81–85. https://doi.org/10.2217/epi-2019-0375
Venter JC et al (2001) The sequence of the human genome. Science 291:1304–1351. https://doi.org/10.1073/pnas.0307971100
Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J (2017) 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet 101:5–22. https://doi.org/10.1016/j.ajhg.2017.06.005
Ward R, Ginsburg GS (2017) Chapter 7–local and global challenges in the clinical implementation of precision medicine. In: Ginsburg GS, Willard HF (eds) Genomic and precision medicine, 3rd edn. Academic, New York, pp 105–117
What is Biotechnology? (2022) Transgenic animals. https://whatisbiotechnology.org/index.php/science/summary/transgenic/transgenic-animals-have-genes-from-other-species-inserted. Accessed 14 May 2022
Willyard C (2018) New human gene tally reignites debate. Nature 558:354–355. https://doi.org/10.1038/d41586-018-05462-w
Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, Berjanskii M, Mah R, Yamamoto M, Jovel J, Torres-Calzada C, Hiebert-Giesbrecht M, Lui VW, Varshavi D, Varshavi D, Allen D, Arndt D, Khetarpal N, Sivakumaran A, Harford K, Sanford S, Yee K, Cao X, Budinski Z, Liigand J, Zhang L, Zheng J, Mandal R, Karu N, Dambrova M, Schiöth HB, Greiner R, Gautam V (2022) HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res 7(50):D622–D631. https://doi.org/10.1093/nar/gkab1062
Yang JH (2022) CRISP(e)R drug discovery. Nat Chem Biol 18:435–436. https://doi.org/10.1038/s41589-022-00979-8
Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (2015) Cpf1 is a single RNA-guided endo-nuclease of a class 2 CRISPR-Cas system. Cell 163:759–771. https://doi.org/10.1016/j.cell.2015.09.038
Zhang HM, Nan ZR, Hui GQ, Liu XH, Sun Y (2014) Application of genomics and proteomics in drug target discovery. Genet Mol Res 13:198–204. https://doi.org/10.4238/2014.January.10.11
Zhao Y, Brasier AR (2016) Qualification and verification of protein biomarker candidates. Adv Exp Med Biol 919:493–514. https://doi.org/10.1007/978-3-319-41448-5_23
Zhao YY, Cheng XL, Lin RC, Wei F (2015) Lipidomics applications for disease biomarker discovery in mammal models. Biomark Med 9:153–168. https://doi.org/10.2217/bmm.14.81
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL (2019) Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570:462–467. https://doi.org/10.1038/s41586-019-1291-3
Zou Y, Laubichler MD (2018) From systems to biology: a computational analysis of the research articles on systems biology from 1992 to 2013. PLoS One 13(7):e0200929. https://doi.org/10.1317/journal.pone.0200929
Acknowledgments
I wish to acknowledge the tremendous contribution of Dr. Arlene Marie Sindelar, my wife, to some of the graphics found in figures in all six editions of this textbook.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sindelar, R.D. (2024). Genomics, Other “OMIC” Technologies, Precision Medicine, and Additional Biotechnology-Related Techniques. In: Crommelin, D.J.A., Sindelar, R.D., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-031-30023-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-30023-3_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-30022-6
Online ISBN: 978-3-031-30023-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)